MedTrace Logo

Study of A3309 in Patients With Dyslipidemia

NCT01069783 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-03-07

No results posted yet for this study

Summary

The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with dyslipidemia (high cholesterol levels).

Conditions

Interventions

DRUG

A3309

A3309 in two different dosage levels

DRUG

A3309

A3309 in two different dosage levels for the duration of the study

DRUG

Placebo

Placebo comparator once daily for the duration of the trial

Sponsors & Collaborators

  • Albireo

    lead INDUSTRY

Principal Investigators

  • Ipsen Medical Director · Ipsen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01069783 on ClinicalTrials.gov